MedTrace Logo

Effects of Salmeterol on Walking Capacity in Patients With COPD

NCT00525564 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2007-09-06

No results posted yet for this study

Summary

This study was designed to test the following hypothesis:

The acute changes in exercise tolerance during the endurance shuttle walk will be greater with salmeterol compared to placebo in patients with chronic obstructive pulmonary disease.

Conditions

Interventions

DRUG

Placebo

Placebo diskus inhalation powder

DRUG

Salmeterol diskus inhalation powder

50 micrograms twice a day

Sponsors & Collaborators

Principal Investigators

  • François Maltais, MD · Laval University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2006-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525564 on ClinicalTrials.gov